Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;13(5):873-888.
doi: 10.1007/s13300-022-01237-9. Epub 2022 Mar 25.

Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

Virginia Bellido  1 , Julia Martínez  2 , Fernando Calvo  3 , Aida Villarroel  2 , Edurne Lecumberri  4 , Juan Moreno  2 , Carlos Morillas  5 , Silvia Rodrigo  2 , Aitziber Izarra  2 , Albert Lecube  6   7
Affiliations
Review

Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

Virginia Bellido et al. Diabetes Ther. 2022 May.

Abstract

Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure (HF) with reduced ejection fraction (EF) and chronic kidney disease (CKD). In monotherapy or as an additive therapy, dapagliflozin aids glycaemic control, is associated with reductions in blood pressure and weight, and promotes a favourable lipid profile. In this review, we address the impact of dapagliflozin on cardiovascular risk factors and common microangiopathic complications such as kidney disease and retinopathy in patients with T2DM. Furthermore, we evaluate its potential beneficial effects on other less frequent complications of diabetes, such as macular oedema, cognitive impairment, non-alcoholic fatty liver disease and respiratory disorders during sleep. Moreover, the underuse of SGLT2i in clinical practice is discussed. Our goal is to help translate this evidence into clinical practice.

Keywords: Cardiometabolic risk factors; Dapagliflozin; Diabetes mellitus; Diabetic angiopathy; Sodium-glucose cotransporter 2 inhibitors; Therapeutic inertia.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Proposed renal and extrarenal mechanism of renal protection by iSGLT2
See this image and copyright information in PMC

References

    1. Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79:1135–1146. doi: 10.1007/s40265-019-01148-3. - DOI - PMC - PubMed
    1. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83–90. doi: 10.1111/j.1463-1326.2011.01517.x. - DOI - PubMed
    1. Centro de información online de medicamentos de la AEMPS (CIMA). Ficha técnica Forxiga [Internet]. Accessed 11 Jun 2021. Available at: https://cima.aemps.es/cima/dochtml/ft/112795007/FT_112795007.html
    1. Leoncini G, Russo E, Bussalino E, Barnini C, Viazzi F, Pontremoli R. SGLT2is and renal protection: from biological mechanisms to real-world clinical benefits. IJMS. 2021;22:4441. doi: 10.3390/ijms22094441. - DOI - PMC - PubMed
    1. Wang D, Luo Y, Wang X, Orlicky DJ, Myakala K, Yang P, et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in Western diet induced obesity mice. Int J Mol Sci. 2018;19(1):137. 10.3390/ijms19010137. - PMC - PubMed